Bonnie J. Howell

Merck & Co., Inc., Rahway, NJ, USA (United States)

Papers

2

Total Citations

12

H-Index

2

About

Dr. Bonnie J. Howell is a leading researcher in infectious disease pharmacology, with a focus on HIV latency reversal and antibacterial drug development. Her work bridges cutting-edge automation with pharmacodynamic modeling to tackle persistent challenges in chronic infections. Dr. Howell’s major contributions include the development of novel in vitro platforms that enable high-throughput, real-time assessment of drug efficacy. Her 2021 study on HIV latency reversal used an automated system to model the pharmacokinetic/pharmacodynamic (PK/PD) profile of histone deacetylase inhibitors (HDACis), providing critical insights into eradicating latent HIV reservoirs—a key barrier to curing chronic infection. In 2022, she advanced antibacterial research by creating a fully automated platform for agar-based measurement of viable bacterial growth, significantly reducing manual labor in dynamic PK/PD studies. Both works have garnered 6 citations each, reflecting their emerging impact. Dr. Howell’s innovative integration of automation into pharmacological modeling is poised to accelerate the translation of preclinical findings into effective therapeutic strategies, making her a pivotal figure in the fight against persistent infectious diseases.

Research Focus

Key Achievements

2
H-Index
2
Papers
12
Total Citations
6
Avg Citations/Paper
🏆 Most Cited Paper
In Vitro Pharmacokinetic/Pharmacodynamic Modeling of HIV Latency Reversal by Novel HDAC Inhibitors Using an Automated Platform
6 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 16
🏛 Institutions: Merck & Co., Inc., Rahway, NJ, USA (United States)

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago